Stammdaten
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Unternehmen & Branche
| Name | NANOVIRICIDES, INC. |
|---|---|
| Ticker | NNVC |
| CIK | 0001379006 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 21,4 Mio. USD |
| Beta | 1,30 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | -2,220,719 | -0.11 | 12,267,640 | 11,071,715 | |
| 2025-09-30 | 10-Q | -1,785,058 | -0.10 | 8,357,080 | 7,174,694 | |
| 2025-06-30 | 10-K | -9,466,966 | -0.63 | 8,824,085 | 7,517,566 | |
| 2025-03-31 | 10-Q | -2,216,783 | -0.14 | 10,031,960 | 8,833,049 | |
| 2024-12-31 | 10-Q | -2,027,491 | -0.14 | 11,570,643 | 10,386,579 | |
| 2024-09-30 | 10-Q | -3,126,811 | -0.23 | 11,740,497 | 10,107,791 | |
| 2024-06-30 | 10-K | -8,294,146 | -0.70 | 12,822,853 | 11,464,077 | |
| 2024-03-31 | 10-Q | -1,854,476 | -0.16 | 11,464,907 | 10,651,570 | |
| 2023-12-31 | 10-Q | -2,114,937 | -0.18 | 13,402,210 | 12,451,136 | |
| 2023-09-30 | 10-Q | -1,968,746 | -0.17 | 15,416,821 | 12,968,510 | |
| 2023-06-30 | 10-K | -8,588,573 | -0.74 | 16,899,880 | 14,865,630 | |
| 2023-03-31 | 10-Q | -1,702,804 | -0.15 | 18,576,799 | 18,228,055 | |
| 2022-12-31 | 10-Q | -1,745,134 | -0.15 | 20,334,963 | 19,870,371 | |
| 2022-09-30 | 10-Q | -1,570,642 | -0.14 | 22,082,335 | 21,563,977 | |
| 2022-06-30 | 10-K | -8,106,863 | -0.70 | 23,494,862 | 23,082,025 | |
| 2022-03-31 | 10-Q | -1,792,664 | -0.16 | 25,144,577 | 24,757,846 | |
| 2021-12-31 | 10-Q | -1,921,134 | -0.17 | 26,809,591 | 26,465,306 | |
| 2021-09-30 | 10-Q | -2,613,068 | -0.23 | 29,178,896 | 28,309,429 | |
| 2021-06-30 | 10-K | -8,822,189 | -0.81 | 30,262,313 | 29,911,167 | |
| 2021-03-31 | 10-Q | -2,108,030 | -0.19 | 32,761,125 | 31,889,781 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.